Samsung Shares Drop as Labor Union Confirms Planned Strike 
Samsung Union Talks Enter Final Stage as Strike Threat Looms 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
Standard Chartered Appoints Manus Costello as New CFO Amid Leadership Reshuffle 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Anthropic to Brief Financial Stability Board on AI-Driven Cyber Risks 
TSMC Stake Sale Sends Vanguard Semiconductor Shares Lower 
YouTube and Snap Settle School District Mental Health Lawsuit Ahead of Major Social Media Trial 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Elliott Targets Bio-Rad as Shares Continue to Struggle 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
Amazon Faces Class-Action Lawsuit Over Trump Tariff Price Hikes 
Tencent Shares Jump 4% as AI Models Move Toward Paid Commercial Services 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
SAN FRANCISCO, Sept. 19, 2016 -- Cantabio Pharmaceuticals, Inc. (OTCQB:CTBO), a biopharmaceutical company developing novel disease modifying therapies for Alzheimer’s, Parkinson’s (PD) and other related neurodegenerative diseases, today announced that members of its senior management team will participate and present in the 2016 Silicon Valley Bank Healthcare Capital and Connections Summit on September 22, 2016 at 4pm in Shanghai, China at the Grand Hyatt Shanghai, Jin Mao Tower.
About Cantabio Pharmaceuticals, Inc.
Cantabio is focused on bringing novel, first-in-class drug candidates into clinical trials and beyond through the discovery and development of innovative pharmacological chaperone and protein delivery based therapeutics, focusing on protein systems implicated in neurodegenerative disorders, including Alzheimer’s and Parkinson’s, and oxidative stress. The company is currently engaged in advanced pre-clinical trials of its therapeutic candidates and is focused on developing these towards clinical trials. More information is available at www.cantabio.com.
Forward-Looking Statements:
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Company contact: Thomas Sawyer, Ph.D., M.B.A. COO Cantabio Pharmaceuticals, Inc. 844-200-CTBO [email protected] Investors and Media Relations: Alex Fudukidis Russo Partners, LLC 646-942-5632 [email protected]
